About Implant Therapeutics
Implant Therapeutics Offers
Hypoimmunogenic and safe harbor engineered IPSC derived cells for:
Why Implant Therapeutics
IPSC-MSC offer cells with the same characteristics as adult derived cells with two advantages:
The ability to make hypoimmunogenic cells make IPSC MSC the choice for bone, cartilage and tendon replacement strategies combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles.
Implant Therapeutics combines the advantages of iPSC-MSC with panCELLa’s exclusive safety platforms to deliver the ultimate therapeutic MSC products.
Experience the Difference
Implant Therapeutic Services
Comprehensive Research & Technology Agreement signed with Angios Biotech and panCELLa.
Our companies are committed to providing the highest quality of cells for therapy. Mahendra Rao, CEO of panCELLa and founder of Implant, notes: “the collaboration of Angios with panCELLa and Implant brings together experts, across two continents, on pluripotent stem cells, gene editing and cell differentiation to treat diseases that require vascular reconstitution. [To read the full story click here]
Accelerating cell-based therapies by providing safe therapeutic MSC products.
Implant Therapeutics, under the guidance of Dr. Mahendra Rao, is engineering iPSC-MSC cells containing panCELLa’s FailSafeTM and induced Allogeneic Cell Tolerance (iACT Stealth CellTM) technologies. These iPSC MSC cells are hypo-immunogenic and are an ideal choice for bone, cartilage and tendon replacement strategies combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles. [To read the full press release click here]